Pfizer to take over Icagen
Currently, Pfizer has 11% ownership of Icagen’s fully diluted shares. Pfizer expects to purchase the remaining 8.3m shares at $6 per share. In 2007, Pfizer and Icagen joined
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.